Latest news with #MG-ActivitiesofDailyLiving

Yahoo

Immunovant's batoclimab shows ‘impressive' efficacy in MG, says H.C. Wainwright

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was encouraged to see the impressive absolute improvements in MG-Activities of Daily Living, the firm acknowledges that the placebo-adjusted readout was mid-pack among FcRn inhibitors-better than nipocalimab but below argenx's (ARGX) Vyvgart and UCB's (UCBY) Rystiggo, the analyst tells investors. The company also reported positive initial CIDP results from Period 1 of the study, which showed that following standard of care washout, patients were randomized into 680mg and 340mg batoclimab only, the firm says. The firm has a Buy rating and $51 price target on Immunovant shares, and says the 'more is better' debate has not yet been settled. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on IMVT: Questions or Comments about the article? Write to editor@ Immunovant Announces Positive Phase 3 Study Results Immunovant announces results from Phase 3 study of batoclimab in MG Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG Immunovant's Phase 3 Trial of Batoclimab: A Catalyst for Future Growth and Market Impact Biohaven price target lowered to $57 from $73 at Bernstein